Drugs / paridiprubart
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01808469 | Nov 2012 → Mar 2014 | — | Light Chain Bioscience - Novimmune SA | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06703073 | Jun 2025 → Jul 2028 expected | acute respiratory distress syndrome | PPD Development, LP | Recruiting | No outcome recorded |
| Phase 2 | NCT06701669 | Jun 2025 → Jul 2028 expected | acute respiratory distress syndrome | PPD Development, LP | Recruiting | No outcome recorded |
| Phase 2 | NCT03241108 | May 2017 → Jun 2018 | rheumatoid arthritis | Light Chain Bioscience - Novimmune SA | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04401475 | Nov 2020 → Dec 2024 | COVID-19, adult acute respiratory distress syndrome | Edesa Biotech Inc. | Suspended | No outcome recorded Stop: Business |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | paridiprubart | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06701669 ↗ |
| Known as | EB05 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04401475 ↗ |
| Known as | NI-0101 | “NI-0101 is an anti-Toll-like receptor monoclonal antibody.” NCT01808469 ↗ |
| Modality | Monoclonal antibody | “NI-0101 is an anti-Toll-like receptor monoclonal antibody.” NCT01808469 ↗ |
| Route | Intravenous | “Single Intravenous Doses of NI-0101” NCT01808469 ↗ |
| Target | TLR4 | “First in Human Study of an Anti-Toll-like Receptor 4 (TLR4) Monoclonal Antibody (NI-0101)” NCT01808469 ↗ |